{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:32:39Z","timestamp":1790069559884,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1136\/ard.2006.068064","type":"journal-article","created":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T00:13:10Z","timestamp":1178583190000},"page":"1162-1167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":622,"title":["Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab"],"prefix":"10.1016","volume":"66","author":[{"given":"Norihiro","family":"Nishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Miyasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamitsu","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2006.068064_bib1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","article-title":"Rheumatoid arthritis: Pathophysiology and implications for therapy","volume":"322","author":"Harris","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2006.068064_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.bor.0000218949.19860.d1","article-title":"Interleukin-6 in rheumatoid arthritis","volume":"18","author":"Nishimoto","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2006.068064_bib3","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.068064_bib4","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1073\/pnas.90.24.11924","article-title":"Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6","volume":"90","author":"Tamura","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.2006.068064_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","article-title":"Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation","volume":"11","author":"Kotake","year":"1996","journal-title":"J Bone Mineral Res"},{"key":"10.1136\/ard.2006.068064_bib6","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/eji.1830181122","article-title":"Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis","volume":"18","author":"Hirano","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1136\/ard.2006.068064_bib7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","article-title":"Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides","volume":"31","author":"Houssiau","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.068064_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI113921","article-title":"Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis","volume":"83","author":"Guerne","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2006.068064_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0090-1229(89)90175-X","article-title":"Constitutive production of interleukin 6\/B cell stimulatory factor-2 from inflammatory synovium","volume":"52","author":"Miyasaka","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1136\/ard.2006.068064_bib10","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.4049\/jimmunol.143.7.2153","article-title":"IL-6\/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides","volume":"143","author":"Bhardwaj","year":"1989","journal-title":"J Immunol"},{"key":"10.1136\/ard.2006.068064_bib11","first-page":"22","article-title":"Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis","volume":"19","author":"Dasgupta","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.068064_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/ard.52.3.232","article-title":"Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity","volume":"52","author":"Madhok","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.068064_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00307733","article-title":"Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis","volume":"13","author":"Sack","year":"1993","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard.2006.068064_bib14","first-page":"2069","article-title":"Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies","volume":"24","author":"Uson","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.068064_bib15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/rheumatology\/40.5.544","article-title":"Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study","volume":"40","author":"Roux-Lombard","year":"2001","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2006.068064_bib16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7","article-title":"Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis","volume":"43","author":"Yamanaka","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.068064_bib17","first-page":"888","article-title":"Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis","volume":"27","author":"Ribbens","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.068064_bib18","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"10.1136\/ard.2006.068064_bib19","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.068064_bib20","first-page":"1426","article-title":"Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I\/II clinical study","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.068064_bib21","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.068064_bib22","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.068064_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.068064_bib24","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.068064_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/art.10181","article-title":"How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion","volume":"47","author":"van der Heijde","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.068064_bib26","first-page":"437","article-title":"Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis","volume":"16","author":"Kashiwazaki","year":"1996","journal-title":"Ensyo"},{"key":"10.1136\/ard.2006.068064_bib27","first-page":"51","article-title":"Rheumatology in Japan, Germany, and Egypt: a comparison of medical practices","volume":"54","author":"Ito","year":"2006","journal-title":"Acta Medica et Biologica"},{"key":"10.1136\/ard.2006.068064_bib28","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the Disease Activity Score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2006.068064_bib29","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.068064_bib30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2006.068064_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60532-5","article-title":"Interleukin-6 in biology and medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Adv Immunol"},{"key":"10.1136\/ard.2006.068064_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1196\/annals.1351.039","article-title":"Effects of Anti-TNF-\u03b1 Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis","volume":"1069","author":"Seriolo","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1136\/ard.2006.068064_bib33","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"10.1136\/ard.2006.068064_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjcard.2006.01.045","article-title":"Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and\/or healed myocardial infarction","volume":"98","author":"Fisman","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1136\/ard.2006.068064_bib35","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/00004872-200310000-00002","article-title":"C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?","volume":"21","author":"Rattazzi","year":"2003","journal-title":"J Hypertens"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724346825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724346825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2006.068064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:33:01Z","timestamp":1736123581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724346825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0003496724346825"],"URL":"https:\/\/doi.org\/10.1136\/ard.2006.068064","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2006.068064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Copyright 2007 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}